This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Results

Model one
The discounted average survival gain in patients treated with pemetrexed plus cisplatin ranged from 0.20 to 0.28 lifeyears compared with cisplatin monotherapy. In terms of QALYs gained, pemetrexed plus cisplatin was associated with gains ranging from 0.13 to 0.20. The associated average incremental costs associated with pemetrexed plus cisplatin treatment ranged from £8,779 to £9,020 compared with cisplatin monotherapy.
The average incremental cost per life-year gained when pemetrexed plus cisplatin was compared with cisplatin monotherapy ranged from £31,337 in patients with advanced disease and performance score 0 or 1 to £44,264 for all patients.
The average incremental cost per QALY gained when pemetrexed plus cisplatin was compared with cisplatin monotherapy ranged from £44,950 in patients with advanced disease and performance score 0 or 1 to £68,599 for all patients.
Model two
Pemetrexed plus cisplatin was associated with increases of 0.521 life-years compared with MVP (mitomycin-C, vinblastine plus cisplatin), 0.218 life-years compared with vinorelbine, and 0.530 life-years compared with active symptom control. Pemetrexed plus cisplatin was associated with increases of 0.350 QALYs compared with MVP, 0.142 QALYs compared with vinorelbine, and 0.356 QALYs compared with active symptom control. Pemetrexed plus cisplatin was associated with incremental costs of £7,604 compared with MVP, £3,748 compared with vinorelbine, and £11,410 compared with active symptom control.
The average incremental cost per life-year gained for pemetrexed plus cisplatin was £14,595 when compared with MVP, £17,156 when compared with vinorelbine, and £21,545 when compared with active symptom control.
The average incremental cost per QALY gained for pemetrexed plus cisplatin was £21,731 when compared with MVP, £26,437 when compared with vinorelbine and £32,066 when compared with active symptom control.
